Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | CCNC | P24863 | 1/20 | 0.53 |
| ▸ | CDK8 | P49336 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27556246 | 1.00 | KMT2A (0.57) | KMT2AALOX15CCNCCDK8ALDH1A1 | |
| SCHEMBL909511 | 0.98 | KMT2A (0.58) | KMT2AALOX15CCNCCDK8ALDH1A1 | |
| SCHEMBL29655599 | 0.98 | KMT2A (0.58) | KMT2AALOX15CCNCCDK8ALDH1A1 | |
| Water SCHEMBL28745933 | 0.96 | KMT2A (0.57) | KMT2AALOX15CCNCCDK8ALDH1A1 | |
| SCHEMBL31123876 | 0.84 | KMT2A (0.56) | KMT2AALOX15CCNCCDK8ALDH1A1 | |
| SCHEMBL876393 | 0.84 | KMT2A (0.56) | KMT2AALOX15CCNCCDK8ALDH1A1 | |
| SCHEMBL13113097 | 0.83 | KMT2A (0.55) | KMT2AALOX15CCNCCDK8ALDH1A1 | |
| SCHEMBL6294601 | 0.82 | KMT2A (0.57) | KMT2AALOX15CCNCCDK8ALDH1A1 | |
| SCHEMBL9163020 | 0.82 | KMT2A (0.53) | KMT2AALOX15CCNCCDK8ALDH1A1 | |
| SCHEMBL29790255 | 0.81 | KMT2A (0.54) | KMT2AALOX15CCNCCDK8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450488-B2 | Process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid and hemipentahydrate monosodium salt thereof | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2013-05-28 | — | — | US | claimed |
| US-20090281320-A1 | PROCESS FOR THE PREPARATION OF [1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE] BISPHOSPHONIC ACID AND HEMIPENTAHYDRATE MONOSODIUM SALT THEREOF | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2009-11-12 | — | — | US | claimed |
| EP-1836210-B1 | PROCESS FOR THE PREPARATION OF [1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDEN]BISPHOSPHONIC ACID AND HEMI-PENTAHYDRATE MONOSODIUM SALT THEREOF | ZAKLADY FARM POLPHARMA SA (PL) | 2008-11-05 | — | — | EP | claimed |
| EP-1836210-A1 | PROCESS FOR THE PREPARATION OF [1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDEN]BISPHOSPHONIC ACID AND HEMI-PENTAHYDRATE MONOSODIUM SALT THEREOF | Zaklady Farmaceutyczne "Polpharma" S.A. (PL) | 2007-09-26 | — | — | EP | claimed |
| WO-2006071128-A1 | PROCESS FOR THE PREPARATION OF [1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDEN] BISPHOSPHONIC ACID AND HEMI-PENTAHYDRATE MONOSODIUM SALT THEREOF | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. (PL) | 2006-07-06 | — | — | WO | claimed |
| CN-108440370-B | Inhibitors of viral replication | 鲁汶天主教大学 | 2021-07-30 | — | — | CN | disclosed |
| CN-108440370-A | Inhibitors of viral replication | 鲁汶天主教大学 | 2018-08-24 | — | — | CN | disclosed |
| CN-104024223-B | Inhibitors of viral replication | 鲁汶天主教大学 | 2018-07-24 | — | — | CN | disclosed |
| CN-104818513-A | ELECTROPLATING CELL, METAL COATING AND METHOD OF FORMING THE SAME | TOYOTA MOTOR CO LTD | 2015-08-05 | — | — | CN | disclosed |
| CN-102656162-B | Novel (heterocycle/tetrahydropyridine)-(piperazinyl)-1-alcanone and (heterocycle/dihydropyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors | SANOFI SA | 2015-07-22 | — | — | CN | disclosed |
| CN-104066724-A | P2X4 receptor antagonists | NIPPON CHEMIPHAR CO | 2014-09-24 | — | — | CN | disclosed |
| CN-104024223-A | Inhibitors of viral replication | UNIV LEUVEN KATH | 2014-09-03 | — | — | CN | disclosed |
| CN-1253547-A | 1,4-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2000-05-17 | — | — | CN | disclosed |
| CN-1242007-A | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising such compounds, and methods of inhibiting beta amyloid peptide release and/or its synthesis using such compounds | ELAND PHARMACEUTICAL CORP (US) | 2000-01-19 | — | — | CN | disclosed |
| CN-1238779-A | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARM INC (US) | 1999-12-15 | — | — | CN | disclosed |
| CN-1238777-A | Erythromycin A derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 1999-12-15 | — | — | CN | disclosed |
| CN-1238760-A | N- (aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions containing such compounds, and methods of inhibiting beta-amyloid peptide release and or synthesis using such compounds | ELAN PHARM INC (US) | 1999-12-15 | — | — | CN | disclosed |
| CN-1237960-A | N (aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and method for inhibiting 'beta'-amyloid peptide release and/or its synthesis by use of such compounds | YEELAN PHARMACEUTICAL CORP (US) | 1999-12-08 | — | — | CN | disclosed |
| CN-1196721-A | Heteroaryl-substituted acryloylguanidine derivatives and medicinal composition thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1998-10-21 | — | — | CN | disclosed |
| CN-1163616-A | DC107 derivatives | KYOWA HAKKO KOGYO KK (JP) | 1997-10-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281320-A1 | PROCESS FOR THE PREPARATION OF [1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE] BISPHOSPHONIC ACID AND HEMIPENTAHYDRATE MONOSODIUM SALT THEREOF | PPA1, PHPT1, HPD | GAA 396/4885KMT2A 3956/4885ALOX15 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.